ArticleHaematologica2025

Terminal complement inhibition and control of hemolysis in patients with paroxysmal nocturnal hemoglobinuria who switched from high-dose eculizumab to ravulizumab: a phase IV, single-arm clinical trial.

Morag Griffin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.